Mixture models and subpopulation classification: A pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 34, Issue 2, 2007, Pages 141-156

  Kaila, Nitin ^a,b   Straka, Robert J ^a   Brundage, Richard C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Mixture models; NONMEM; Pharmacokinetics; Phenotype

Indexed keywords

CYTOCHROME P450 2D6; METOPROLOL;

ACCURACY; ADULT; ARTICLE; ASSAY; CLASSIFICATION; CLEARANCE; COVARIANCE; DRUG METABOLISM; HUMAN; MALE; MODEL; NORMAL HUMAN; PHENOTYPE; POPULATION; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2D6; HUMANS; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MODELS, BIOLOGICAL; PHENOTYPE; POPULATION SURVEILLANCE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SMOKING;

EID: 34047209775     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9038-9     Document Type: Article

References (23)

1. R. Hussein, B. G. Charles, R. G. Morris, and R. L. Rasiah. Population pharmacokinetics of perhexiline from very sparse, routine monitoring data. Ther. Drug Monit. 23:636-643 (2001).
2. B. Frame, R. Miller, and R. L. Lalonde. Evaluation of mixture modeling with count data using NONMEM. J. Pharmacokinet. Pharmacodyn. 30:167-183 (2003).
3. B. Facca, B. Frame, and S. Triesenberg. Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients. Antimicrob. Agents Chemother. 42:1783-1787 (1998).
4. K. O. Borg et al. Metabolism of metoprolol-(3-h) in man, the dog and the rat. Acta Pharmacol. Toxicol. (Copenh). 36(Suppl):125-135 (1975).
5. S. V. Otton, H. K. Crewe, M. S. Lennard, G. T. Tucker, and H. F. Woods. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247:242-247 (1988).
6. J. A. Johnson and B. S. Burlew. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab. Dispos. 24:350-355 (1996).
7. http://www.imm.ki.se/CYPalleles/. Human cytochrome P450 (CYP) allele nomenclature committee. Criteria for inclusion, and nomenclature files [online].
8. D. S. Streetman, J. S. Bertino Jr., and A. N. Nafziger. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216 (2000).
9. G. Alvan, P. Bechtel, L. Iselius, and U. Gundert-Remy. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39:533-537 (1990).
10. L. Bertilsson and M. L. Dahl. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5:200-223 (1996).
11. L. Bertilsson et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51:388-397 (1992).
12. D. A. Evans, A. Mahgoub, T. P. Sloan, J. R. Idle, and R. L. Smith. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 17:102-105 (1980).
13. I. Johansson et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90:11825-11829 (1993).
14. M. L. Dahl, I. Johansson, M. P. Palmertz, M. Ingelman-Sundberg, and F. Sjoqvist. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther. 51:12-17 (1992).
15. M. L. Dahl, I. Johansson, L. Bertilsson, M. Ingelman-Sundberg, and F. Sjoqvist. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274:516-520 (1995).
16. J. Wikstrand et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982 (1988).
17. R. J. Straka, K. A. Johnson, C. R. Gross, R. C. Brundage, and J. W. McBride. Pharmacodynamic modeling of metoprolol enantiomers in poor and extensive metabolizers of debrisoquin. Clin. Pharmacol. Ther. 49:157 (1991).
18. R. J. Straka, P. S. Marshall, K. A. Johnson, J. C. Carr, and J. W. McBride. The effects of smoking on post exercise heart rate and metoprolol enantiomeric pharmacodynamics in extensive metabolisers of dextromethorphan. Pharmacotherapy 12(3):1992 (1992).
19. R. J. Straka, K. A. Johnson, P. S. Marshall, and R. P. Remmel. Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase. J. Chromatogr. 530:83-93 (1990).
20. R. J. Straka, S. R. Hansen, and P. F. Walker. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol. Ther. 58:29-34 (1995).
21. J. Kirchheiner et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76:302-312 (2004).
22. I. Zineh et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76:536-544 (2004).
23. L. J. Schaaf, B. R. Dobbs, I. R. Edwards, and D. G. Perrier. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur. J. Clin. Pharmacol. 32:411-418 (1987).